FULCRUM THERAPEUTICS INC. - COMMON STOCK
3.8200
04-October-24 15:59:57
15 minutes delayed
Stocks
+0.1550
+4.23%
Today's range
3.6850 - 3.8400
ISIN
N/A
Source
NASDAQ
-
27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
20 Feb 2024 16:01:00 By Nasdaq GlobeNewswire
-
06 Feb 2024 08:00:01 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Dec 2023 16:30:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2023 16:30:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
31 Oct 2023 08:50:33 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
22 Sep 2023 08:00:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Sep 2023 16:30:00 By Nasdaq GlobeNewswire
-
07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire
-
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
22 Aug 2023 07:00:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Aug 2023 16:53:28 By Nasdaq GlobeNewswire
-
03 Aug 2023 07:01:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Appoints Chief Financial Officer
03 Aug 2023 06:55:00 By Nasdaq GlobeNewswire
-
27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
10 Jul 2023 07:00:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jul 2023 17:30:31 By Nasdaq GlobeNewswire
-
20 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Jun 2023 16:54:20 By Nasdaq GlobeNewswire